Updated

The FDA wants to withdraw its approval of the drug Tavneos, saying it was approved on the basis of manipulated study data, Ars Technica reported on October 31, 2026. The agency's move raises the question of whether patients should keep access. The process for withdrawing approval is complicated, and the outlet notes that the question of patient access remains open.